DE69926606T2 - Plazentaprotein 13 - Google Patents
Plazentaprotein 13 Download PDFInfo
- Publication number
- DE69926606T2 DE69926606T2 DE69926606T DE69926606T DE69926606T2 DE 69926606 T2 DE69926606 T2 DE 69926606T2 DE 69926606 T DE69926606 T DE 69926606T DE 69926606 T DE69926606 T DE 69926606T DE 69926606 T2 DE69926606 T2 DE 69926606T2
- Authority
- DE
- Germany
- Prior art keywords
- protein
- amino acid
- sequence
- acid sequence
- cdna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102100022898 Galactoside-binding soluble lectin 13 Human genes 0.000 claims description 55
- 101000620927 Homo sapiens Galactoside-binding soluble lectin 13 Proteins 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 108020004414 DNA Proteins 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 230000035935 pregnancy Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 9
- 102000053602 DNA Human genes 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000012086 standard solution Substances 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000013615 primer Substances 0.000 description 12
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108091060211 Expressed sequence tag Proteins 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 5
- 102100024637 Galectin-10 Human genes 0.000 description 5
- 239000001099 ammonium carbonate Substances 0.000 description 5
- 235000012501 ammonium carbonate Nutrition 0.000 description 5
- 108010089086 lysolecithin acylhydrolase Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 3
- 206010070531 Foetal growth restriction Diseases 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 208000005107 Premature Birth Diseases 0.000 description 3
- 206010036590 Premature baby Diseases 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000030941 fetal growth restriction Diseases 0.000 description 3
- 108091005573 modified proteins Proteins 0.000 description 3
- 102000035118 modified proteins Human genes 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 208000012113 pregnancy disease Diseases 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000002787 Pregnancy Complications Diseases 0.000 description 2
- 102000008217 Pregnancy Proteins Human genes 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000701988 Escherichia virus T5 Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710158668 Placental protein Proteins 0.000 description 1
- 108010035746 Pregnancy Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical class [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/97—Test strip or test slide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/822—Identified hapten
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/824—Immunological separation techniques
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL123098 | 1998-01-29 | ||
| IL12309898A IL123098A0 (en) | 1998-01-29 | 1998-01-29 | Placental protein 13 |
| PCT/IL1999/000036 WO1999038970A1 (en) | 1998-01-29 | 1999-01-21 | Placental protein 13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69926606D1 DE69926606D1 (de) | 2005-09-15 |
| DE69926606T2 true DE69926606T2 (de) | 2006-06-08 |
Family
ID=11071151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69926606T Expired - Lifetime DE69926606T2 (de) | 1998-01-29 | 1999-01-21 | Plazentaprotein 13 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6548306B1 (enExample) |
| EP (1) | EP1051487B1 (enExample) |
| JP (1) | JP2002516658A (enExample) |
| AR (1) | AR018045A1 (enExample) |
| AT (1) | ATE301713T1 (enExample) |
| AU (1) | AU2071799A (enExample) |
| CA (1) | CA2319699C (enExample) |
| DE (1) | DE69926606T2 (enExample) |
| DK (1) | DK1051487T3 (enExample) |
| ES (1) | ES2246563T3 (enExample) |
| IL (2) | IL123098A0 (enExample) |
| WO (1) | WO1999038970A1 (enExample) |
| ZA (1) | ZA99677B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123098A0 (en) * | 1998-01-29 | 1998-09-24 | Diagnostic Technologies Ltd | Placental protein 13 |
| IL129273A (en) * | 1999-03-30 | 2003-10-31 | Diagnostic Technologies Ltd | Monoclonal antibody to placental protein 13 and immunoassay and kit using said antibody |
| JP2003519162A (ja) * | 2000-01-03 | 2003-06-17 | ティーアール アソシエイツ，エル．エル．シー． | Ｐｐ１４融合蛋白質並びに該蛋白質の製造及び使用方法 |
| AU2003256036B2 (en) * | 2002-08-29 | 2009-02-26 | Diagnostic Technologies Ltd. | Method of diagnosis of pregnancy-related complications |
| WO2007086067A1 (en) * | 2006-01-30 | 2007-08-02 | Diagnostic Technologies Ltd. | Method for monitoring tocolytic treatment |
| WO2007088543A1 (en) * | 2006-02-02 | 2007-08-09 | Diagnostic Technologies Ltd. | A method for determining the effectiveness of a treatment for preeclampsia |
| EP2038431A1 (en) * | 2007-02-01 | 2009-03-25 | Diagnostic Technologies Ltd. | Method for determining preeclampsia risk |
| CN112341533A (zh) * | 2020-11-20 | 2021-02-09 | 东北师范大学 | 无标签人半乳糖凝集素13及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444879A (en) * | 1981-01-29 | 1984-04-24 | Science Research Center, Inc. | Immunoassay with article having support film and immunological counterpart of analyte |
| DE3230996A1 (de) * | 1982-08-20 | 1984-02-23 | Behringwerke Ag, 3550 Marburg | Neues protein (pp(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)3(pfeil abwaerts)), verfahren zu seiner anreicherung und gewinnung sowie seine verwendung |
| US5198366A (en) * | 1986-03-23 | 1993-03-30 | Technion Research & Development Foundation Ltd. | Method for the detection of pregnancy disorders |
| ATE78342T1 (de) | 1987-03-24 | 1992-08-15 | Technion Res & Dev Foundation | Verfahren zur feststellung von schwangerschaftsstoerungen. |
| IL123098A0 (en) * | 1998-01-29 | 1998-09-24 | Diagnostic Technologies Ltd | Placental protein 13 |
-
1998
- 1998-01-29 IL IL12309898A patent/IL123098A0/xx not_active IP Right Cessation
-
1999
- 1999-01-21 EP EP99901094A patent/EP1051487B1/en not_active Expired - Lifetime
- 1999-01-21 DE DE69926606T patent/DE69926606T2/de not_active Expired - Lifetime
- 1999-01-21 CA CA002319699A patent/CA2319699C/en not_active Expired - Fee Related
- 1999-01-21 AU AU20717/99A patent/AU2071799A/en not_active Abandoned
- 1999-01-21 DK DK99901094T patent/DK1051487T3/da active
- 1999-01-21 JP JP2000529430A patent/JP2002516658A/ja active Pending
- 1999-01-21 ES ES99901094T patent/ES2246563T3/es not_active Expired - Lifetime
- 1999-01-21 IL IL13749799A patent/IL137497A0/xx unknown
- 1999-01-21 AT AT99901094T patent/ATE301713T1/de not_active IP Right Cessation
- 1999-01-21 WO PCT/IL1999/000036 patent/WO1999038970A1/en not_active Ceased
- 1999-01-21 US US09/601,178 patent/US6548306B1/en not_active Expired - Fee Related
- 1999-01-28 AR ARP990100341A patent/AR018045A1/es unknown
- 1999-01-28 ZA ZA9900677A patent/ZA99677B/xx unknown
-
2002
- 2002-11-05 US US10/287,639 patent/US7211405B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK1051487T3 (da) | 2005-11-14 |
| CA2319699C (en) | 2007-06-12 |
| ATE301713T1 (de) | 2005-08-15 |
| CA2319699A1 (en) | 1999-08-05 |
| US6548306B1 (en) | 2003-04-15 |
| US20030092188A1 (en) | 2003-05-15 |
| JP2002516658A (ja) | 2002-06-11 |
| IL137497A0 (en) | 2001-07-24 |
| AU2071799A (en) | 1999-08-16 |
| DE69926606D1 (de) | 2005-09-15 |
| ES2246563T3 (es) | 2006-02-16 |
| WO1999038970A1 (en) | 1999-08-05 |
| EP1051487A1 (en) | 2000-11-15 |
| EP1051487B1 (en) | 2005-08-10 |
| US7211405B2 (en) | 2007-05-01 |
| ZA99677B (en) | 1999-09-02 |
| IL123098A0 (en) | 1998-09-24 |
| AR018045A1 (es) | 2001-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69130506T2 (de) | Nukleotidsequenzen kodierend für ein humanes protein mit angiogenetisch-regulatorischen eigenschaften | |
| Takahashi et al. | Cloning and sequencing of cDNA of Sarcophaga peregrina humoral lectin induced on injury of the body wall. | |
| EP0471701B2 (de) | Neue proteine mit tnf-hemmender wirkung und ihre herstellung | |
| DE69117949T2 (de) | Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis | |
| DE69534252T2 (de) | Enzyme zur spaltung der verankerungsregion von oberflächenproteinen aus gram-positiven bakterien | |
| EP1923465A1 (de) | Inhibitor-Protein des WNT-Signalwegs | |
| DE69117123T2 (de) | Menschliches MK Gen und Protein-Sequenz | |
| DE69231567T2 (de) | Screeningverfahren von morphogenischen Proteinen | |
| DE69926606T2 (de) | Plazentaprotein 13 | |
| DE69229219T2 (de) | Neuartige, physiologisch aktive substanz epimorphin, für sie kodierende gene und antikörper gegen epimorphin | |
| DE69532874T2 (de) | RPDL Protein und kodierende DNS | |
| DE69922489T2 (de) | Rekombinantes aktives humanes Zona Pellucida | |
| DE69329190T2 (de) | Autotaxin : ein das selbständige zellbewegungsvermögen stimulierendes protein nützlich in der krebs-diagnostik und therapie | |
| DE69534958T2 (de) | Modifiziertes Epimorphin | |
| DE69836278T2 (de) | Allele formen von menschlichem stat3 | |
| DE69031996T2 (de) | Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung | |
| DE4444753C2 (de) | Antibiotisch wirksame Peptide aus der bovinen Milch, deren Gewinnung und Verwendung | |
| EP1007671B1 (de) | Fanconi-gen ii | |
| DE69433221T2 (de) | Neues Chondrozytprotein | |
| DE602004004312T2 (de) | Allergenes Kautschuk-Protein | |
| DE102006059574B4 (de) | Verfahren und Reagenzien zur spezifischen Detektion von Autoantikörpern bei Patienten mit blasenbildenden Autoimmundermatosen | |
| DE69519654T2 (de) | htFIIIA Gen | |
| DE69827808T2 (de) | Protease-ähnliches protein | |
| Veiby et al. | Amino Acid Sequence Analyses of Non‐AA Proteins from Amyloid Fibrils of Bovine Kidney | |
| DE19808258A1 (de) | Kopfaktivator-bindendes Protein oder Polypeptid und Verfahren zur Suche nach funktionalen Agonisten oder Antagonisten unter Verwendung von kopfaktivatorbindendem Protein oder Polypeptid |